Details from the source.
Source-listed Semaglutide (SKU SM10): 10mg*10vials. PriceList(1).pdf lists 43 per 10 vials but does not specify currency; the website displays $43 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- SM10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- Owner-supplied photograph; visible package label matched to this catalogue entry. Supplier identity, lot, and product quality have not been independently verified.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Semaglutide is a peptide analogue of human GLP-1 and a GLP-1 receptor agonist. This classifies the known molecule, not the unidentified contents of any catalogue vial.
Biological mechanism
Semaglutide activates GLP-1 receptors. The pathway affects glucose regulation and appetite: it can increase glucose-dependent insulin secretion, reduce glucagon when blood glucose is elevated, delay gastric emptying, and reduce appetite and caloric intake. Animal studies described in FDA labeling found activation of brain regions involved in food-intake regulation. Exact mechanisms for cardiovascular risk reduction and MASH treatment are not fully established. [1]
Research focus
Human research and approved uses of specific branded semaglutide formulations include weight reduction and long-term weight management, cardiovascular-event risk reduction in certain adults with established cardiovascular disease and overweight or obesity, and treatment of noncirrhotic MASH with moderate-to-advanced fibrosis. The MASH indication for WEGOVY is under accelerated approval. These findings apply to studied or labeled products and eligible populations, not automatically to this catalogue listing. [1] [2]
Potential applications in the evidence
The clinical applications investigated in identified semaglutide products include weight management, cardiovascular risk reduction for certain adults with established cardiovascular disease and overweight or obesity, and MASH treatment in a defined adult population. FDA-approved indications belong to specific formulations and conditions; they do not establish efficacy or approval for the listed supplier vial. [1] [2]
Human evidence
In the STEP 1 randomized trial, 1,961 adults with overweight or obesity and without diabetes received semaglutide or placebo alongside lifestyle intervention for 68 weeks. Mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo. Nausea and diarrhea were most common; gastrointestinal events led to discontinuation in 4.5% versus 0.8%. These findings establish results for the trial product, regimen, population, and setting only—not for the Yinyu-listed vial strengths or an unverified formulation. [4]
Known and potential effects
FDA WEGOVY labeling reports common adverse reactions including nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension and other gastrointestinal symptoms. Warnings include pancreatitis, gallbladder disease, hypoglycemia (especially with insulin or insulin-secretagogue medicines), kidney injury associated with volume depletion, severe gastrointestinal reactions, allergic reactions, diabetic-retinopathy complications, increased heart rate, and aspiration during general anesthesia or deep sedation. [1] [3]
Safety and contraindications
The FDA label has a boxed warning for thyroid C-cell tumors observed in rodents; whether this risk applies to humans is unknown. WEGOVY is contraindicated for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or known hypersensitivity to semaglutide or product ingredients. FDA labeling also warns of potential fetal harm. This general safety information is not an assessment of the catalogue vial or personal medical advice. [1]
U.S. FDA / regulatory status
FDA has approved specific semaglutide medicines and formulations, including WEGOVY, OZEMPIC and RYBELSUS. Approval of the active ingredient or a branded product does not transfer to a supplier-specific vial. The supplied list does not provide enough information to verify whether any listed vial is FDA-approved, compounded, or research-only; do not assign any of those categories without product documentation. FDA cautions that compounded products are not FDA-reviewed for premarket safety, effectiveness, or quality, and that semaglutide sodium and acetate salts differ from the base form used in approved drugs. That caution does not establish that this item is compounded or contains a salt form. [1] [2] [3]
Evidence limitations
The supplied PDF lists Semaglutide under SKUs SM5, SM10, SM15, SM20 and SM30, with specifications `*10vials`, `*10vials`, `*10vials`, `*10vials`, `*10vials` and prices 30, 43, 56, 69 and 89 respectively; it states no currency. These are transcriptions, not verified product contents. No manufacturer, lot, exact formulation or chemical form, label, jurisdiction, regulatory authorization, concentration, or quality documentation is supplied. The listing alone cannot verify identity, content, sterility, purity, manufacturing quality, or approval. Human results from identified products and animal-model findings cannot validate these catalogue vials. [1] [3] [4]
Supporting sources
- Wegovy semaglutide prescribing information, revised February 2026 U.S. Food and Drug Administration · Official prescribing label. Supports: Peptide classification, mechanism, FDA-labeled indications and formulations, contraindications, warnings, adverse effects, and distinction between animal and human evidence.
- FDA Drugs@FDA record for WEGOVY NDA 215256 U.S. Food and Drug Administration · Regulatory drug database. Supports: Specific FDA-approved branded product and presentation records and approval history; does not identify the Yinyu catalogue vial.
- FDA alert on dosing errors associated with compounded injectable semaglutide U.S. Food and Drug Administration · Safety communication. Supports: Compounded-product safety caveats, reported dosing-error harms, approved brand distinctions, and warning that salt forms differ from the base form in approved drugs.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity, STEP 1 trial New England Journal of Medicine; abstract hosted by PubMed, U.S. National Library of Medicine · Primary randomized clinical trial. Supports: Human STEP 1 trial population, duration, weight outcomes, common adverse effects, and gastrointestinal discontinuation.